Vortioxetine tablets — Competitive Intelligence Brief

Vortioxetine tablets (Vortioxetine tablets) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin modulator and stimulator. Area: Psychiatry.

phase 3 Serotonin modulator and stimulator 5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter Psychiatry Small molecule

Target snapshot

Vortioxetine tablets (Vortioxetine tablets) — Takeda. Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vortioxetine tablets TARGET	Vortioxetine tablets	Takeda	phase 3	Serotonin modulator and stimulator	5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter
Vortioxetine (Lu AA21004)	Vortioxetine (Lu AA21004)	H. Lundbeck A/S	phase 3	Serotonin modulator and stimulator	5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin modulator and stimulator class)

1. H. Lundbeck A/S · 1 drug in this class
2. Takeda · 1 drug in this class